Across TCGA pan-cancer cohorts, MLIP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MLIP data layer compared with 26 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MLIP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MLIP expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.
PDAC, HNSC, and LSCC are the cancer types where MLIP mass-spec protein most reproducibly stratifies survival.